SRGN抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08805(SRGN Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Serglycin (SRGN) antibodies target a proteoglycan initially identified in hematopoietic cells, where it plays a key role in storing and secreting granular components (e.g., proteases, cytokines) within vesicles. SRGN consists of a core protein modified by glycosaminoglycan (GAG) chains, typically chondroitin sulfate, which mediate interactions with extracellular ligands. Beyond its physiological roles in immune cells, SRGN is implicated in cancer progression. Overexpression of SRGN in tumor cells or tumor-associated stromal cells (e.g., macrophages) correlates with enhanced metastasis, angiogenesis, and chemoresistance. SRGN facilitates these effects by modulating signaling pathways (e.g., NF-κB, STAT3) and extracellular matrix remodeling.

Antibodies against SRGN have emerged as tools for studying its functional contributions to disease. They enable detection of SRGN expression in tissues, serving as potential biomarkers for aggressive cancers. Therapeutic applications are under exploration, particularly in blocking SRGN-mediated interactions that promote tumor-microenvironment crosstalk. Challenges include SRGN’s structural heterogeneity (due to variable GAG modifications) and its dual roles in different cell types, necessitating antibody specificity validation. Recent studies also highlight SRGN’s involvement in non-cancer pathologies (e.g., inflammation), expanding its relevance as a target. Current research focuses on optimizing SRGN antibodies for diagnostic and therapeutic precision.